Weight loss effects vary by population, with clinical trials showing up to 21-22% mean weight loss in obesity trials (non-diabetes patients) and lower percentages in type 2 diabetes patients, depending on dose
Patients should seek urgent medical attention for severe persistent abdominal pain, as pancreatitis and biliary disease remain potential risks even after gallbladder removal
(3) insufficient sample size in some subgroups (e.g., 54 cases in the 360 days
Total body fat percentage slightly decreased (from 65% to 63.7%), and significant improvements were noted in insulin resistance, liver transaminase levels, and lipid profiles
Click for more information Vitamin D Uses Calcium from your diet for strong bones and teeth Click for more information Vitamin E Dissolves fat, helps prevent heart disease, cancer & treats diabetes
For a full breakdown of how tirzepatide works as a dual GIP/GLP-1 agonist, see the overview guide